OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Opko Health, Inc.

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
On Friday, Lineage's CO-EXECUTIVE CHAIRMAN, Kevin Patrick Marchetti, made a $995,216 purchase of LINE, buying 23,540 shares at a cost of $42.28 each. Bargain hunters can pick up LINE even cheaper than Marchetti did, with shares trading as low as $40.10 in trading on Tuesday -- that's 5.2% under Marchetti's purchase price. Lineage is trading up about 1.9% on the day Tuesday. Before this latest buy, Marchetti purchased LINE at 3 other times during the past twelve months, for a total cost of $1.99M at an average of $51.30 per share.
And also on Friday, CEO & Chairman Phillip Frost bought $891,000 worth of OPKO Health, buying 675,000 shares at a cost of $1.32 each. Before this latest buy, Frost bought OPK on 15 other occasions during the past twelve months, for a total cost of $4.56M at an average of $1.54 per share. OPKO Health is trading up about 2.7% on the day Tuesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tuesday 8/12 Insider Buying Report: LINE, OPK

Key Points
Revenue (GAAP) missed expectations, falling to $156.8 million in Q2 2025—down approximately 14% from the prior year quarter and 5.4% below analyst estimates.
GAAP net loss deepened to $0.19 per share, with nonrecurring charges worsening overall results in Q2 2025.
Diagnostics revenue dropped sharply after asset sales, but operating losses in the segment improved in Q2 2025.
Opko Health (NASDAQ:OPK), a diversified healthcare company operating in diagnostics and pharmaceuticals, released its second quarter 2025 results on July 31, 2025. The company reported a significant revenue miss, with total GAAP revenue at $156.8 million, compared to analyst expectations of $165.7 million for Q2 2025. Its net loss per share on a GAAP basis reached $0.19, wider than estimates for a $0.11 loss and sharply higher than the prior-year figure in Q2 2025. Results were affected by lower diagnostics revenues due to asset sales, flat pharmaceutical product revenues, and the impact of a one-time charge related to a convertible note exchange in Q2 2025. Cost-cutting and divestitures helped reduce some operating losses, but overall, the quarter underscored ongoing restructuring and financial challenges for the business.
Metric
Q2 2025
Q2 2025 Estimate
Q2 2024
Y/Y Change
EPS (GAAP)
($0.19)
($0.11)
($0.01)
1,800%
Revenue (GAAP)
$156.8 million
$165.7 million
$182.2 million
(14.0%)
Operating Loss
($60.0 million)
($61.7 million)
-2.8%
Pharmaceuticals Revenue
$40.7 million
$40.5 million
0.5%
Diagnostics Revenue
$101.1 million
$129.4 million
(21.8%)
Business Overview and Recent Focus
Opko Health focuses on two main business areas: pharmaceutical products and diagnostics services. Its pharmaceutical portfolio includes therapies for chronic kidney disease, hormonal disorders, and infectious diseases. Its diagnostics unit, BioReference, provides medical laboratory testing, including specialized cancer screening.
Recently, the company has been working to streamline operations through asset sales and cost reductions, particularly within its diagnostics business. Managing regulatory approvals for both medication and diagnostic tests, along with investing in research and partnerships, are also key drivers for the company’s performance.
Quarterly Highlights and Developments
The quarter saw a substantial drop in consolidated revenues, primarily due to declining diagnostics sales following the sale of certain BioReference assets in Q2 2025. Diagnostics revenue (GAAP) fell to $101.1 million, down from $129.4 million in Q2 2024. This revenue contraction was a direct result of asset divestitures, though BioReference’s ongoing cost-cutting and restructuring led to improved operating results for the reduced business in Q2 2025.
Pharmaceutical revenues stayed nearly flat versus the previous year, at $40.7 million in Q2 2025. Rayaldee’s performance was unchanged, with $7.2 million in revenue for both Q2 2025 and Q2 2024. NGENLA, a once-weekly growth hormone injection marketed by Pfizer, saw profit share slide from $6.3 million in Q2 2024 to $6.1 million. These results highlight a lack of revenue growth in the company’s most important product lines, with product revenue at $40.7 million in Q2 2025 compared to $40.5 million in Q2 2024, and Rayaldee sales steady at $7.2 million for both periods, underscoring the need for new growth drivers from the existing pipeline.
On the pipeline and partnership front, regulatory advances were a bright spot. The U.S. Food and Drug Administration (FDA) approved a supplemental application for the 4Kscore test, a blood test that helps assess the likelihood of aggressive prostate cancer. This approval is expected to expand access to more physicians, particularly as most primary care providers do not routinely perform digital rectal exams. In research and development, OPKO continued to invest in multiple early-stage programs, including immunotherapies in collaboration with major partners such as Merck, and advanced work on GLP-1/glucagon therapies aimed at metabolic liver disease.
One-time financial actions had a major impact on the quarter’s reported results. The company recognized a $91.7 million nonrecurring charge related to the exchange of convertible notes for equity and cash during Q2 2025. While this substantially worsened the reported net loss, it was not a recurring operating expense. Additionally, OPKO’s board authorized an extra $100 million in share repurchase capacity, with $58.5 million spent under the program as of the end of Q2 2025. The company’s cash position shrank to $285.4 million as of June 30, 2025, down from $431.9 million at year-end 2024.
Product Lines and Innovation Pipeline
OPKO Health’s pharmaceutical business is anchored by Rayaldee, an oral vitamin D prohormone for patients with chronic kidney disease, and NGENLA, a human growth hormone therapy developed with Pfizer for pediatric growth hormone deficiency. Rayaldee sales held steady at $7.2 million in Q2 2025. NGENLA’s gross profit share also remained nearly flat and has not yet demonstrated a rebound in Q2 2025, despite prescription growth suggested by public data. There was no material growth from other pharmaceutical products to offset these trends.
The diagnostics segment, led by BioReference, focuses on medical laboratory testing. The 4Kscore prostate cancer test, designed to predict the risk of aggressive disease using a blood sample, received FDA approval for expanded use during Q2 2025. However, the segment as a whole continues to see revenue pressure after recent asset divestitures. The company expects further revenue reduction upon the anticipated sale of its oncology testing assets to Labcorp, a leading laboratory services company. Operating costs in the diagnostics segment have come down sharply, and management expects that the remaining core operations will be profitable before nonrecurring and noncash expense items.
Financial Outlook and Key Watch Items
Management maintained its full-year 2025 revenue guidance of $675 million to $685 million, despite the weak quarter. This implies a substantially stronger performance in the second half of the year. The company also guided for full-year 2025 costs and expenses of $825 million to $875 million. BARDA contract revenue guidance for 2025 was slightly lowered, and research and development spending is expected to remain elevated, reflecting ongoing investment in early-stage programs supported by the Biomedical Advanced Research and Development Authority (BARDA).
These include the impact of additional cost reduction initiatives expected to reach $10 million annually, and the anticipated completion of the Labcorp asset sale, which will reshape the diagnostics business. Returning to profitability in core diagnostics and pharmaceutical operations remains a key target. No new dividend was declared, and OPK does not currently pay a dividend. Cash burn and share count dilution are ongoing areas of focus, particularly as research spending continues and new product launches remain at least a year or more away.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of July 29, 2025
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Opko Health (OPK) Q2 Revenue Falls 14%

OPKO Health, Inc. OPK delivered a loss per share of 19 cents in the second quarter of 2025, wider than the year-ago period’s loss of a penny per share and the Zacks Consensus Estimate of a loss of 12 cents per share.
OPK’s Revenues in Detail
OPKO Health registered revenues of $156.8 million in the second quarter, down 13.9% year over year. The figure missed the Zacks Consensus Estimate by 5.1%.
The overall top line was dampened by lower revenues from services, which were partly offset by strength in revenues from products, and the transfer of intellectual property and other.
Shares of this company lost nearly 3.1% during after-hours trading.
OPKO Health’s Segmental Revenues
OPKO Health manages its operations through two reportable segments – Diagnostics and Pharmaceuticals.
Within the Diagnostics arm, revenues from services amounted to $101.1 million in the reported quarter, down 21.9% year over year. This was primarily due to lower clinical test volume, principally as a result of the sale of certain BioReference assets, partially offset by higher clinical test reimbursement rates. This compares to our projection of $104.9 million from services revenues in the second quarter.
Within the Pharmaceuticals arm, revenues from products inched up 0.6% year over year to $40.7 million, reflecting higher sales volumes in certain international operations. This was partially offset by reduced sales in the Chilean subsidiary due to the impact of foreign currency and a mild winter cold and flu season. This compares to our projection of $41.8 million from product revenues in the second quarter.
Revenues from sales of Rayaldee in the second quarter of 2025 were $7.2 million, flat from the prior-year period.
Revenues from the transfer of intellectual property and other totaled $14.9 million, up 21.6% from the prior-year period. This increase was driven by higher revenue from the BARDA contract and contract manufacturers’ commercial milestones. This was partially offset by lower gross profit share payments for NGENLA, which totaled $6.1 million in the 2025 period compared with $6.3 million in the 2024 period. This compares to our projection of $17.9 million in revenues from the transfer of intellectual property and other in the second quarter.
OPKO Health, Inc. Price, Consensus and EPS Surprise
OPK’s Margin Analysis
In the quarter under review, OPKO Health’s gross profit decreased 4.4% year over year to $49.4 million. However, the gross margin expanded 315 basis points (bps) to 31.5%.
Selling, general and administrative (SG&A) expenses declined 13.4% year over year to $59.6 million. Research and development expenses increased 25.9% year over year to $30.3 million. Adjusted operating expenses of $89.9 million decreased 3.2% year over year.
Adjusted operating loss totaled $40.5 million compared with the prior-year quarter’s adjusted operating loss of $41.3 million.
OPKO Health’s Financial Position
OPKO Health exited second-quarter 2025 with cash and cash equivalents of $271.7 million compared with $435.9 million at the first-quarter end.
Cumulative net cash used in operating activities at the end of second-quarter 2025 was $117.9 million compared with $62 million a year ago.
OPK’s Guidance
OPKO Health has revised its financial outlook for 2025.
For the full year, it now expects total revenues between $640 million and $660 million, down from the prior outlook of $675 million and $685 million. The Zacks Consensus Estimate currently stands at $651.8 million.
Revenues from product sales are now expected to be in the range of $160 million-$170 million, down from the prior outlook of $165 million-$175 million.
Revenues from services are expected to be in the range of $405 million-$425 million.
Other revenues are now expected to be between $65 million and $75 million, lowered from the prior outlook of $75 million and $85 million. This includes the Pfizer gross profit share estimates between $28 million and $35 million (lowered from $30 million and $40 million) and support from BARDA of $30 million to $35 million (lowered from $38 million to $44 million).
Our Take on OPKO Health
OPKO Health exited the second quarter of 2025 with a wider-than-expected loss per share and lower-than-expected revenues. Its dismal top-and-bottom-line performances and lower revenues from services were disappointing. The persistent operating loss also does not bode well for the company.
On a positive note, robust revenues from products, and transfer of intellectual property and other were registered during the quarter. The expansion of the gross margin bodes well for the company.
During the quarter, OPKO Health’s ModeX continued to advance its immuno-oncology and immunology portfolio with four potential clinical candidates progressing, while Merck advanced a Phase 1 Epstein-Barr virus vaccine trial, which is being developed in collaboration with OPK. During the quarter, the FDA approved the supplemental application for the 4KScore Test regarding the availability of digital rectal examination information. These developments look promising for the stock.
OPK’s Zacks Rank and Stocks to Consider
OPK currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX.
GE HealthCare, carrying a Zacks Rank #2 (Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GE HealthCare has a long-term estimated growth rate of 7.4%. GEHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
FTI CONSULTING INC (FCN) is a mid-cap growth stock in the Business Services industry. The rating according to our strategy based on Kenneth Fisher changed from 58% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: FTI Consulting, Inc. is a global business advisory company. The Companys segment includes Corporate Finance & Restructuring segment focuses on the strategic, operational, financial, transactional and capital needs of its clients; Forensic and Litigation Consulting segment provides law firms, companies, government entities and other interested parties with a multidisciplinary and independent range of services in risk and investigations and disputes; Economic Consulting segment provides law firms, companies, and government entities with analyzes of economic issues for use in international arbitration and legal and regulatory proceedings and strategic decision-making and public policy debates; Technology segment provides companies, law firms, private equity firms and government entities with a portfolio of digital insights and risk management consulting and data services, and Strategic Communications segment provides corporate reputation, financial communications and public affairs.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of FTI CONSULTING INC
OPKO HEALTH INC (OPK) is a small-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Companys segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of OPKO HEALTH INC
LIMONEIRA CO (LMNR) is a small-cap growth stock in the Crops industry. The rating according to our strategy based on Kenneth Fisher changed from 58% to 70% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Limoneira Company is primarily an agribusiness company. Its operations consist of fruit production, sales and marketing, rental operations, real estate and capital investment activities. It operates in three business divisions: agribusiness, rental operations, and real estate development. The agribusiness division includes four segments, such as fresh lemons, lemon packing, avocados and other agribusiness, which primarily includes oranges, specialty citrus, other crops and farm management services. The agribusiness division includes farming, harvesting, lemon packing and lemon sales operations. The rental operations division includes its residential and commercial rentals, leased land operations and organic recycling. The real estate development division includes its investments in real estate development projects. It markets and sells lemons directly to its food service, wholesale and retail customers throughout the United States, Canada, Asia, and other international markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of LIMONEIRA CO
VIMEO INC (VMEO) is a small-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Kenneth Fisher changed from 58% to 70% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Vimeo, Inc. operates a video experience platform, providing a full breadth of video tools through a software-as-a-service (SaaS) model. The Companys core focus is transforming how people create and share videos by providing products and a platform that bridges technology with creative innovation. The Company provides a turnkey cloud-based solution that eliminates barriers to using video and solves essential video needs, including video hosting and management, intuitive video creation and editing, insightful analytics, artificial intelligence (AI) language translations, and enterprise tools. It sells subscription plans including add-ons to its self-serve subscriptions, Vimeo Enterprise, and over-the-top (OTT), and provides additional features beyond its self-serve plans, such as dedicated support, account management, service level agreements, and professional live event services. Its users include creative professionals, marketers, filmmakers, and digital agencies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of VIMEO INC
ZEVIA PBC (ZVIA) is a small-cap growth stock in the Beverages (Non-Alcoholic) industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Zevia PBC is a beverage company. It develops, markets, sells, and distributes naturally delicious, zero-sugar beverages. The Companys beverages are plant-based ingredients, contain no artificial sweeteners, and are non-GMO project verified, gluten-free, Kosher, and vegan. It markets its products under the Zevia brand across multiple beverage categories, including Soda, Energy Drinks and Organic Teas. Its flagship product, Soda, is available in 18 flavors across multiple packs, variety packs, and in limited time-offer flavors. It offers Energy drinks in eight flavors. Organic Tea is a zero-calorie, naturally sweetened ready-to-drink tea segment. It offers Organic Tea in eight flavors, including one caffeine-free option. Zevia products are distributed in more than 37,000 retail locations in the United States and Canada through a diverse network of retailers in the grocery, drug, warehouse club, mass, natural, convenience and ecommerce channels.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of ZEVIA PBC
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 8/1/2025

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
OMNICELL INC (OMCL) is a small-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Kenneth Fisher changed from 50% to 70% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The CompanyGs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
PASS
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of OMNICELL INC
OMCL Guru Analysis
OMCL Fundamental Analysis
ANGIODYNAMICS, INC. (ANGO) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of ANGIODYNAMICS, INC.
ANGO Guru Analysis
ANGO Fundamental Analysis
OPKO HEALTH INC (OPK) is a small-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The CompanyGs segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of OPKO HEALTH INC
OPK Guru Analysis
OPK Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 6/18/2025

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic partnerships. However, stiff competition and overdependence on RAYALDEE pose concerns.
Shares of this Zacks Rank #3 (Hold) company have lost 8.8% so far this year compared with the industry's 9.7% decline. The S&P 500 has increased 2.1% in the said time frame.
This renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.07 billion. The company predicts 33.3% growth for fiscal 2026 and expects to maintain its strong performance. OPKO Health’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average beat being 65.33%.
Image Source: Zacks Investment Research
Factors Favoring OPK Stock
Potential of RAYALDEE: Rayaldee remains OPKO Health’s flagship renal product in the United States, approved for treating SHPT in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. Distributed primarily through retail pharmacies and major wholesalers, Rayaldee also operates under various rebate and discount agreements with payors and providers. While sales declined recently due to headwinds from the Inflation Reduction Act, OPKO reported improved operating margins driven by better net pricing through reduced government rebates, which helped partially offset the volume decline.
Strategic Agreements: OPKO Health has been active on multiple strategic fronts. In March, the company partnered with Entera Bio to develop a once-daily oral GLP-1/glucagon dual agonist tablet targeting obesity and metabolic disorders, combining OPKO’s OPK-88006 analog with Entera’s N-Tab delivery tech. That same month, OPKO also reached an agreement with Labcorp, which will acquire select oncology and diagnostics assets from OPKO’s BioReference Health. This divestiture, including a similar sale in September 2024, is expected to streamline operations, strengthen focus on the $300 million 4Kscore urology franchise, and potentially raise up to $462.5 million to support business expansion and debt reduction.
Clinical Trials: In its latestearnings call OPKO Health confirmed that ModeX Therapeutics has two active programs in Phase 1 trials: an Epstein-Barr virus (EBV) vaccine candidate in collaboration with Merck, and MDX2001, a tetraspecific antibody targeting solid tumors, which has progressed to its fourth dose level. Additional Phase 1 and 1b studies in selected solid tumors are expected to begin in early 2026. Human trials for MDX2003 (for lymphoma and leukemia) and MDX2004 (an immune rejuvenator) are planned for late 2025 or early 2026. Meanwhile, the development of multispecific antibodies for immunocompromised patients at risk for COVID-19 and influenza continues, backed by $110 million in BARDA funding.
Factors That May Offset the Gains for OPK
Overdependence on RAYALDEE: OPKO Health's financial success depends heavily on the commercialization of Rayaldee, its only approved pharmaceutical product in the United States. Failure to effectively market Rayaldee could severely affect the company's revenues, profitability and overall business operations.
Additionally, Rayaldee's market reputation, safety and perceived efficacy are crucial. Any negative publicity, safety concerns or rumors about the product could significantly harm OPKO's business, undermining the product's acceptance and damaging its financial outlook.
Currently, reimbursement challenges, increased competition and slower-than-expected market adoption are likely to hurt Rayaldee sales going forward. Moreover, pricing pressures and formulary restrictions, along with shifts in treatment guidelines and generic alternatives, are likely to keep the drug’s sales under pressure.
Stiff Competition: The pharmaceutical, diagnostic, and laboratory testing industries are highly competitive and require an ongoing, extensive search for technological innovation. Numerous companies, including major pharmaceutical companies, specialty pharmaceutical companies and specialized biotechnology companies, are engaged in the development, manufacture and marketing of pharmaceutical products competitive with those that OPKO Health intends to commercialize itself and through its partners.
Competitors to the company’s diagnostics business include major diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resources. This enables them to make greater research and development investments and efficiently utilize their research and development costs, as well as their marketing and promotion costs, over a broader revenue base. OPKO Health’s major competitors include Quest Diagnostics and Laboratory Corporation of America.
Estimate Trend of OPK
OPKO Health is witnessing a negative estimate revision trend for 2025. In the past 60 days, the Zacks Consensus Estimate for its loss has widened from 25 cents to 30 cents per share.
The Zacks Consensus Estimate for the company’s second-quarter 2025 revenues and loss per share is pegged at $165.4 million and 10 cents, respectively. The revenue estimate indicates a 9.2% decline from the year-ago quarter’s reported number.
Stocks to Consider
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO.
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report
CVS Health Corporation (CVS) : Free Stock Analysis Report
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
OPKO HEALTH INC (OPK) is a small-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The CompanyGs segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of OPKO HEALTH INC
OPK Guru Analysis
OPK Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 5/29/2025

OPKO Health, Inc. OPK delivered a loss per share of 10 cents in the first quarter of 2025, narrower than the year-ago period’s loss of 12 cents per share. However, the metric was wider than the Zacks Consensus Estimate of a loss of 6 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
OPK’s Revenues in Detail
OPKO Health registered revenues of $149.9 million in the first quarter, down 13.7% year over year. The figure missed the Zacks Consensus Estimate by 8.9%.
The overall top line was dampened by lower revenues from products and services, which was partly offset by strength in revenues from the transfer of intellectual property.
Shares of this company lost nearly 1.4% at the end of yesterday’s trading.
OPKO Health’s Segmental Revenues
OPKO Health manages its operations through two reportable segments – Diagnostics and Pharmaceuticals.
Within the Diagnostics arm, revenues from services amounted to $102.8 million in the reported quarter, down 18.9% year over year. This was primarily due to lower clinical test volume, principally resulting from the sale of certain assets of BioReference Health (BioReference), partially offset by higher clinical test reimbursement rates. This compares to our projection of $101 million from services revenues in the first quarter.
Within the Pharmaceuticals arm, revenues from products declined 8.7% year over year to $34.8 million, reflecting unfavorable foreign currency exchange fluctuations and a decrease in Rayaldee sales. This compares to our projection of $40.2 million from product revenues in the first quarter.
Revenues from sales of Rayaldee in the first quarter of 2025 were $6.3 million, down 8.7% from the prior-year period.
Revenues from the transfer of intellectual property totaled $12.3 million, up 41.4% from the prior-year period. This increase was driven by revenues from the BARDA contract of $7 million in 2025 compared with $2.2 million in 2024. This increase was partially offset by a decrease in gross profit share payments for NGENLA, which totaled $4.5 million in the first quarter of 2025 compared with $5.6 million in the year-ago period. This compares to our projection of $20.2 million in revenues from the transfer of intellectual property in the first quarter.
OPKO Health, Inc. Price, Consensus and EPS Surprise
OPKO Health, Inc. price-consensus-eps-surprise-chart | OPKO Health, Inc. Quote
OPK’s Margin Analysis
In the quarter under review, OPKO Health’s gross profit increased 1.4% year over year to $42.6 million. The gross margin expanded 424 basis points to 28.4%.
Selling, general and administrative expenses declined 15.8% year over year to $59.1 million. Research and development expenses increased 40.6% year over year to $30.8 million. Adjusted operating expenses of $89.9 million decreased 2.4% year over year.
Adjusted operating loss totaled $47.3 million compared with the prior-year quarter’s adjusted operating loss of $50.1 million.
OPKO Health’s Financial Position
OPKO Health exited first-quarter 2025 with cash and cash equivalents of $436 million compared with $431.9 million at 2024-end.
OPK’s Guidance
OPKO Health has revised its financial outlook for 2025.
For the full year, it now expects total revenues between $675 million and $685 million, narrowed from the prior outlook of $675 million and $700 million. The Zacks Consensus Estimate currently stands at $671.9 million.
Revenues from product sales are continued to be expected in the range of $165 million-$175 million.
Other revenues are now expected to be between $75 million and $85 million, lowered from the prior outlook of $80 million and $95 million. This includes the Pfizer gross profit share estimates between $30 million and $40 million (lowered from $35 million and $45 million) and BARDA revenues of $38 million to $44 million (lowered from $40 million to $48 million).
Our Take
OPKO Health exited the first quarter of 2025 with a wider-than-expected loss per share and lower-than-expected revenues. Its dismal top-and-bottom-line performances and lower revenues from products and services were disappointing. The decline in Rayaldee sales was also concerning. The persistent operating loss also does not bode well for the company.
On a positive note, robust revenues from the transfer of intellectual property were registered during the quarter. The expansion of the gross margin bodes well for the company.
During the quarter, OPKO Health signed a definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference, which includes the sale of BioReference’s laboratory testing businesses focused on oncology and oncology-related clinical testing services. The company also entered into a collaboration agreement with Entera Bio to advance an oral GLP-1/glucagon tablet candidate into the clinic to treat obesity and metabolic disorders. Also, OPKO Health’s company, ModeX Therapeutics Inc., continued to advance its immuno-oncology and immunology portfolio with four potential clinical candidates progressing in the pipeline. These developments look promising for the stock.
OPKO Health’s Zacks Rank and Key Picks
OPK currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are Encompass Health Corporation EHC, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX.
Encompass Health, carrying a Zacks Rank #2 (Buy), reported first-quarter 2025 adjusted EPS of $1.37, beating the Zacks Consensus Estimate by 15.1%. Revenues of $1.46 billion outpaced the consensus mark by 1.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Encompass Health has a long-term estimated growth rate of 9.8%. EHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.3%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 13.3%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Encompass Health Corporation (EHC) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
On Friday, OPKO Health's CEO & Chairman, Phillip Frost, M.D et. al., made a $254,385 buy of OPK, purchasing 150,000 shares at a cost of $1.70 each. Bargain hunters can bag OPK even cheaper than Frost did, with shares changing hands as low as $1.62 at last check today which is 4.5% under Frost's purchase price. OPKO Health is trading down about 1.2% on the day Wednesday. Before this latest buy, Frost bought OPK at 12 other times during the past twelve months, for a total cost of $3.95M at an average of $1.55 per share.
And on Tuesday, CEO Celeste Beeks Mastin bought $198,310 worth of Fuller, buying 3,500 shares at a cost of $56.66 a piece. This purchase marks the first one filed by Mastin in the past year. Fuller is trading up about 0.5% on the day Wednesday.
VIDEO: Wednesday 4/2 Insider Buying Report: OPK, FUL
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Wednesday 4/2 Insider Buying Report: OPK, FUL

Labcorp LH recently entered into an agreement with OPKO Health, Inc. OPK, a multinational biopharmaceutical and diagnostics company, to acquire select assets of the latter’s wholly owned subsidiary, BioReference Health. This acquisition will strengthen Labcorp's position in the oncology industry, expanding its extensive portfolio of diagnostic tests in cancer care.
Financial Details
The purchase price for the transaction is up to $225 million, including $192.5 million payable at closing and up to $32.5 million in an earnout based on performance. The proposed acquisition meets Labcorp's strategic and financial criteria and is expected to be accretive to its earnings in the first year.
More Details on Labcorp’s Acquisition Deal
Labcorp will acquire OPKO’s BioReference Health's laboratory testing businesses focused on oncology and oncology-related clinical testing services across the United States. This transaction includes certain customer accounts and other operating assets. The assets that Labcorp will be acquiring currently generate approximately $85 million to $100 million in annual revenues.
The transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities. On closing of the transaction, BioReference Health's operations will include core clinical testing operations in the New York and New Jersey region and its 4Kscore franchise.
The transaction is subject to customary closing conditions and remaining applicable state regulatory approvals. The company expects to close the acquisition transaction in the second half of 2025.
Industry Prospects Favor Labcorp
Per the Grand View Research report, the global cancer diagnostics market size is expected to grow at a compound annual rate of 6.14% from 2025 to 2030. The growth of the cancer diagnostics market is attributed to the growing prevalence of cancer, technological advancements in diagnostics procedures and increasing initiatives to develop novel imaging solutions for providing more accurate and precise diagnosis.
Sridatri
Other Recent Developments by Labcorp
In the previous month, the company’s Labcorp Plasma Complete, a circulating tumor DNA-based comprehensive genomic profiling solution, became clinically available for patients with advanced solid tumors. This liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions.
Also, the company announced the expansion of its laboratory in Raritan, NJ. The expansion adds 110,000 square feet of advanced laboratory space and a state-of-the-art warehouse and logistics hub, strengthening Labcorp’s position as a leader in diagnostic testing and healthcare innovation. With over 1,300 laboratory professionals working at the Raritan site, the laboratory processes specimens from more than 110,000 patients daily.
Latest Updates From Labcorp’s Peers
In the oncology space, Labcorp faces competition from some prominent MedTech players. These companies are also making notable developments within this category.
Illumina ILMN, one of the major competitors of Labcorp, is driving the revolution in cancer genomics through an expanding NGS oncology portfolio. In 2024, the FDA approved Illumina’s in vitro diagnostic TSO Comprehensive test and its first two companion diagnostic indications. The test interrogates more than 500 genes to profile a patient's solid tumor, identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. Meanwhile, its market-leading TruSight Oncology assay, TSO 500, is witnessing increased utilization and broader adoption.
Another competitor of Labcorp is NeoGenomics, Inc. NEO, which recently announced the acquisition of Pathline, LLC. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast United States, expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company. Additionally, NeoGenomics signed a multi-year exclusive strategic commercial collaboration with Adaptive Biotechnologies Corporation to advance MRD monitoring options for patients with select blood cancers.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Labcorp (LH) : Free Stock Analysis Report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
NeoGenomics, Inc. (NEO) : Free Stock Analysis Report
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.